Mark A. Frye, MD
Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.; Corresponding Author: Mark A. Frye, MD, Department of Psychiatry and Psychology, Mayo Clinic, 200 First St SW, Rochester, MN 55905 ([email protected]).
Original Research
Ketamine vs Esketamine for TRD
February 1, 2023
Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.
Letter to the Editor
BMI and Remission in Depressed Patients Receiving IV Ketamine
November 12, 2019
Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...
Article
Illness Progression as a Function of Independent and Accumulating Poor Prognosis Factors in Outpatients With Bipolar Disorder in the United States
December 18, 2014
Many patients with bipolar disorder in the United States experience a deteriorating course of illness despite naturalistic treatment in the community. In this study, Post and colleagues explored this...
